Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
- Affiliated Author(s)
- 김미경
- Alternative Author(s)
- Kim, Mi Kyung
- Journal Title
- Diabetes & Metabolism Journal
- ISSN
- 2233-6079
- Issued Date
- 2016
- Keyword
- Dipeptidyl peptidase 4 inhibitor; Metformin; Thiazolidinediones
- Abstract
- Background: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an addon
treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes.
Methods: The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin
and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient
underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin.
Results: The mean changes in HbA1c levels from baseline were –0.94% in the vildagliptin group and –0.6% in the pioglitazone
group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial
plasma glucose (PPG) levels were –60.2 mg/dL in the vildagliptin group and –38.2 mg/dL in the pioglitazone group and
these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high
density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean
change in body weight was –0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly
different (P=0.002).
Conclusion: As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to
that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects
on PPG levels, lipid profiles, and body weight compared to pioglitazone.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.